# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Henry Holliday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI007-SYN
- Date: 2026-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Martin Beaumont, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

End of the intensive phase: two-month sputum and the start of the continuation phase. **S**

## History of present illness

Mr. Holliday returns after nine weeks of treatment. He completed the 56 doses of the intensive phase six days ago, and pyrazinamide was stopped; he now takes isoniazid, rifampin, and pyridoxine daily by video. The cultures from the third week show no growth so far, with the final reading due next week. His cough has gone, and he has gained weight. He has had no nausea, yellowing, dark urine, or numbness. He has had no alcohol for seven weeks and sees his counselor every two weeks. He is working full days. **S**

| Element | Detail |
|---|---|
| Treatment | Intensive phase complete; continuation phase started six days ago |
| Symptoms | No cough, fever, or night sweats |
| Weight | 62.5 kg, up 4.5 kg since diagnosis |
| Alcohol | None for seven weeks; AUDIT-C 1 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough, sputum, or blood |
| Constitutional | Negative | No fever or night sweats; appetite good |
| Gastrointestinal | Negative | No nausea or abdominal pain |
| Psychiatric | Negative | Mood good; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Isoniazid 300 mg tablet, one tablet daily **S**
- Rifampin 300 mg capsules, two capsules (600 mg) daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/74 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 62.5 kg; BMI 19.7 kg/m². All vital signs are synthetic.

ALT: 38 U/L; AST: 35 U/L; Total bilirubin: 0.7 mg/dL; AUDIT-C: 1. All results are synthetic.

## Change since baseline

- ALT: 34 U/L at baseline, 38 U/L at this visit **S**
- AST: 38 U/L at baseline, 35 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.7 mg/dL at this visit **S**
- AUDIT-C: 9 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 62.5 kg |
| Eyes | No icterus |
| Respiratory | Clear apart from a few fine crackles at the right apex |
| Abdomen | Liver not enlarged or tender |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Drug-susceptible pulmonary tuberculosis, continuation phase** (A15.0). Intensive phase complete with full adherence and a good clinical response. Liver tests normal (ALT 38, AST 35, bilirubin 0.7). Because the disease was cavitary, the two-month culture taken today decides the length of the continuation phase: four months if negative, seven if positive. Dr. Navarro reviewed the plan by message today and agreed. **S**
   - Continue isoniazid 300 mg, rifampin 600 mg, and pyridoxine daily by video.
   - Sputum smear and culture today (induced, because he no longer coughs up sputum).
   - Monthly liver tests and symptom review continue.
2. **Alcohol use disorder, mild** (F10.10). No alcohol for seven weeks. Safety reviewed: no thoughts of suicide. **S**
   - Continue counseling every two weeks.
   - Plan ahead for social events where he used to drink.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | At least monthly during treatment | Completed today | No symptoms |
| Examination | Weight | At least monthly during treatment | Completed today | 62.5 kg |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | None |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, at two weeks, then monthly because of alcohol use | Completed today | ALT 38, AST 35 U/L, bilirubin 0.7 mg/dL, all normal |
| Laboratory | Two-month sputum culture | At the end of the intensive phase; decides the continuation length in cavitary disease | Completed today | Induced sputum smear negative today; culture sent, final reading in six weeks |
| Laboratory | Sputum AFB smear and culture | Monthly until two consecutive cultures are negative | Completed today | Third-week cultures show no growth so far; final next week |
| Imaging | Chest X-ray | At diagnosis; at two months only if the first cultures were negative; at the end of treatment as a new baseline | Not indicated | Not needed at two months, because the first cultures were positive |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | All 56 intensive-phase doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy |
| Referral | Contact investigation (household, coworkers, patients) | Led by the health department, from diagnosis | Referred | Health department continuing; no results are part of his record |
| Survey | Alcohol use (AUDIT-C for the past month) | Every visit | Completed today | AUDIT-C 1 for the past month |
| Self-management | Brief counseling about alcohol and liver risk | Every visit | Completed today | Social events planned for |
| Referral | Counseling with a substance-use counselor | Every one to two weeks during treatment | Completed today | Every two weeks |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide |
| Referral | Infectious diseases review | At two months and at the end of treatment | Completed today | Dr. Navarro reviewed the plan by message today |

## Goal progress

- Complete 182 doses of treatment under video-observed therapy within six months. In progress; target 2026-08-18. **S**
- Sputum culture negative at two months. In progress; target 2026-08-18. **S**
- No alcohol during treatment, to protect his liver. In progress; target 2026-08-18. **S**
- Return to work once he is no longer infectious. Outcome by 2026-03-17: Released from home isolation after three negative sputum smears and back at work four weeks into treatment. **S**
- Weight back to at least 64 kg by the end of treatment. In progress; target 2026-08-18. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- End-of-treatment visit after the last dose. Monthly liver tests and symptom review in between. Call the same day for hepatitis symptoms or a returning cough. **S**
- Next scheduled visit 2026-08-18: end-of-treatment review after six months. **S**
